Progress in the development of new therapies for herpesvirus infections

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 548-554

  Price, Nathan B ^a   Prichard, Mark N ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 DEOXY BETA DEXTRO RIBOFURANOSYL) 6 (4 PENTYLPHENYL) 2,3 DIHYDRO[2,3 D]PYRIMIDIN 2 ONE; AIC 246; AIC 361; ANTIVIRUS AGENT; BAY 571293; BENZIMIDAVIR; CF 1743; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOPROPAVIR; DNA POLYMERASE; FV 100; GANCICLOVIR; MBX 400; N [5 (AMINOSULFONYL) 4 METHYL 1,3 THIAZOL 2 YL] N METHYL 2 [4 (2 PYRIDINYL)PHENYL]; NUCLEOSIDE ANALOG; OMACICLOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VALOMACICLOVIR;

ADENOVIRUS INFECTION; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN CYTOMEGALOVIRUS; INFECTION RESISTANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VIRUS INHIBITION;

EID: 82955173057     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.10.015     Document Type: Review

References (62)

1. V.C. Emery, and P.D. Griffiths Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy Proc Natl Acad Sci U S A 97 2000 8039 8044 (Pubitemid 30460769)
2. G. Torres-Madriz, and H.W. Boucher Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients Clin Infect Dis 47 2008 702 711
3. N.S. Lurain, and S. Chou Antiviral drug resistance of human cytomegalovirus Clin Microbiol Rev 23 2010 689 712
4. L. Strasfeld, and S. Chou Antiviral drug resistance: mechanisms and clinical implications Infect Dis Clin North Am 24 2010 809 833
5. K.K. Biron Antiviral drugs for cytomegalovirus diseases Antiviral Res 71 2006 154 163 (Pubitemid 44223768)
6. G. Andrei, E. De Clercq, and R. Snoeck Drug targets in cytomegalovirus infection Infect Disord Drug Targets 9 2009 201 222
7. J. Piret, and G. Boivin Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management Antimicrob Agents Chemother 55 2011 459 472
8. G.B. Elion Mechanism of action and selectivity of acyclovir Am J Med 73 1982 7 13 (Pubitemid 12067749)
9. C. McGuigan, H. Barucki, A. Carangio, S. Blewett, G. Andrei, R. Snoeck, E. De Clercq, J. Balzarini, and J.T. Erichsen Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain J Med Chem 43 2000 4993 4997 (Pubitemid 32039020)
10. C. McGuigan, R.N. Pathirana, M. Migliore, R. Adak, G. Luoni, A.T. Jones, A. Diez-Torrubia, M.J. Camarasa, S. Velazquez, and G. Henson Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus J Antimicrob Chemother 60 2007 1316 1330 (Pubitemid 350168329)
11. R. Sienaert, L. Naesens, A. Brancale, E. De Clercq, C. McGuigan, and J. Balzarini Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase Mol Pharmacol 61 2002 249 254 (Pubitemid 34112797)
12. H.S. Pentikis, M. Matson, G. Atiee, B. Boehlecke, J.T. Hutchins, J.M. Patti, G.W. Henson, and A. Morris Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers Antimicrob Agents Chemother 55 2011 2847 2854
13. S. Biswas, and H.J. Field Helicase-Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus 2011 WILEY-VCH Verlag GmbH & Co. Weinheim
14. G. Kleymann, R. Fischer, U.A. Betz, M. Hendrix, W. Bender, U. Schneider, G. Handke, P. Eckenberg, G. Hewlett, and V. Pevzner New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease Nat Med 8 2002 392 398 (Pubitemid 34407035)
15. G. Kleymann Agents and strategies in development for improved management of herpes simplex virus infection and disease Expert Opin Investig Drugs 14 2005 135 161 (Pubitemid 40403389)
16. S. Biswas, R.N. Miguel, S. Sukla, and H.J. Field A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure J Gen Virol 90 2009 1937 1942
17. S. Biswas, M. Swift, and H.J. Field High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1 Antivir Chem Chemother 18 2007 13 23 (Pubitemid 46426934)
18. S. Sukla, S. Biswas, A. Birkmann, P. Lischka, H. Ruebsamen-Schaeff, H. Zimmermann, and H.J. Field Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant Antiviral Res 87 2010 67 73
19. H.J. Field, and S. Biswas Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus Drug Resist Update 14 2011 45 51
20. D.M. Lowe, W.K. Alderton, M.R. Ellis, V. Parmar, W.H. Miller, G.B. Roberts, J.A. Fyfe, R. Gaillard, P. Ertl, and W. Snowden Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses Antimicrob Agents Chemother 39 1995 1802 1808
21. E. De Clercq Guanosine analogues as anti-herpesvirus agents Nucleosides Nucleotides Nucleic Acids 19 2000 1531 1541 (Pubitemid 32065108)
22. G. Andrei, R. Snoeck, D. Reymen, C. Liesnard, P. Goubau, J. Desmyter, and E. De Clercq Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus Eur J Clin Microbiol Infect Dis 14 1995 318 329
23. T.I. Ng, Y. Shi, H.J. Huffaker, W. Kati, Y. Liu, C.M. Chen, Z. Lin, C. Maring, W.E. Kohlbrenner, and A. Molla Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy) butyl]guanine Antimicrob Agents Chemother 45 2001 1629 1636 (Pubitemid 32466327)
24. M.J. Hitchcock, H.S. Jaffe, J.C. Martin, and R.J. Stagg Cidofovir, a new agent with potent anti-herpesvirus activity Antivir Chem Chemother 7 1996 115 127 (Pubitemid 26150100)
25. K.Y. Hostetler Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art Antiviral Res 82 2009 A84 A98
26. S.L. Williams-Aziz, C.B. Hartline, E.A. Harden, S.L. Daily, M.N. Prichard, N.L. Kushner, J.R. Beadle, W.B. Wan, K.Y. Hostetler, and E.R. Kern Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro Antimicrob Agents Chemother 49 2005 3724 3733 (Pubitemid 41233024)
27. S.H. James, C.B. Hartline, E.A. Harden, E.M. Driebe, J.M. Schupp, D.M. Engelthaler, P.S. Keim, T.L. Bowlin, E.R. Kern, and M.N. Prichard Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase Antimicrob Agents Chemother 55 2011 4682 4691
28. D.J. Bidanset, J.R. Beadle, W.B. Wan, K.Y. Hostetler, and E.R. Kern Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection J Infect Dis 190 2004 499 503 (Pubitemid 38982087)
29. E.R. Kern, D.J. Collins, W.B. Wan, J.R. Beadle, K.Y. Hostetler, and D.C. Quenelle Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir Antimicrob Agents Chemother 48 2004 3516 3522 (Pubitemid 39129353)
30. F.J. Bravo, D.I. Bernstein, J.R. Beadle, K.Y. Hostetler, and R.D. Cardin Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection Antimicrob Agents Chemother 55 2011 35 41
31. D.C. Quenelle, B. Lampert, D.J. Collins, T.L. Rice, G.R. Painter, and E.R. Kern Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies J Infect Dis 202 2010 1492 1499
32. M.N. Prichard, E.R. Kern, C.B. Hartline, E.R. Lanier, and D.C. Quenelle CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections Antimicrob Agents Chemother 55 2011 4728 4734
33. G.R. Painter, L.C. Trost, B.L. Lambert, M.R. Almond, M. Buller, E.R. Kern, G.P. Painter, A.T. Robertson, and R. O'Mahony CMX001 Drugs of the Future 33 2008 1 7
34. S.L. Ciesla, J. Trahan, W.B. Wan, J.R. Beadle, K.A. Aldern, G.R. Painter, and K.Y. Hostetler Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney Antiviral Res 59 2003 163 171 (Pubitemid 36966748)
35. S.L. Williams, C.B. Hartline, N.L. Kushner, E.A. Harden, D.J. Bidanset, J.C. Drach, L.B. Townsend, M.R. Underwood, K.K. Biron, and E.R. Kern In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses Antimicrob Agents Chemother 47 2003 2186 2192 (Pubitemid 36753570)
36. K. Biron E. Bogner, A. Holzenburg, Maribavir: A Promising New Antiherpes Therapeutic Agent 2006 Springer Dordrecht, The Netherlands
37. E.R. Kern, C.B. Hartline, R.J. Rybak, J.C. Drach, L.B. Townsend, K.K. Biron, and D.J. Bidanset Activities of benzimidazole d- and l-ribonucleosides in animal models of cytomegalovirus infections Antimicrob Agents Chemother 48 2004 1749 1755 (Pubitemid 38544384)
38. M.N. Prichard Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir Rev Med Virol 19 2009 215 229
39. S. Chou Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir Rev Med Virol 18 2008 233 246 (Pubitemid 352018847)
40. S. Chou, and G.I. Marousek Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus Antimicrob Agents Chemother 50 2006 3470 3472 (Pubitemid 44527529)
41. S. Chou Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir Antimicrob Agents Chemother 53 2009 81 85
42. G. Komazin, L.B. Townsend, and J.C. Drach Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides J Virol 78 2004 710 715 (Pubitemid 38067592)
43. J.M. Reitsma, J.P. Savaryn, K. Faust, H. Sato, B.D. Halligan, and S.S. Terhune Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest Cell Host Microbe 9 2011 103 114
44. A.J. Hume, J.S. Finkel, J.P. Kamil, D.M. Coen, M.R. Culbertson, and R.F. Kalejta Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function Science 320 2008 797 799 (Pubitemid 351929629)
45. M.N. Prichard, E. Sztul, S.L. Daily, A.L. Perry, S.L. Frederick, R.B. Gill, C.B. Hartline, D.N. Streblow, S.M. Varnum, and R.D. Smith Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes J Virol 82 2008 5054 5067 (Pubitemid 351657065)
46. S. Hamirally, J.P. Kamil, Y.M. Ndassa-Colday, A.J. Lin, W.J. Jahng, M.C. Baek, S. Noton, L.A. Silva, M. Simpson-Holley, and D.M. Knipe Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress PLoS Pathog 5 2009 e1000275
47. M. Marschall, A. Marzi, P. aus dem Siepen, R. Jochmann, M. Kalmer, S. Auerochs, P. Lischka, M. Leis, and T. Stamminger Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina J Biol Chem 280 2005 33357 33367 (Pubitemid 41397133)
48. F.M. Marty, P. Ljungman, G.A. Papanicolaou, D.J. Winston, R.F. Chemaly, L. Strasfeld, J.A. Young, T. Rodriguez, J. Maertens, and M. Schmitt Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial Lancet Infect Dis 11 2011 284 292
49. S. Zhou, J.M. Breitenbach, K.Z. Borysko, J.C. Drach, E.R. Kern, E. Gullen, Y.C. Cheng, and J. Zemlicka Synthesis antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides J Med Chem 47 2004 566 575 (Pubitemid 38129715)
50. E.R. Kern, N.L. Kushner, C.B. Hartline, S.L. Williams-Aziz, E.A. Harden, S. Zhou, J. Zemlicka, and M.N. Prichard In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication Antimicrob Agents Chemother 49 2005 1039 1045 (Pubitemid 40327721)
51. E.R. Kern, D.J. Bidanset, C.B. Hartline, Z. Yan, J. Zemlicka, and D.C. Quenelle Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections Antimicrob Agents Chemother 48 2004 4745 4753 (Pubitemid 39577680)
52. B.G. Gentry, J.P. Kamil, D.M. Coen, J. Zemlicka, and J.C. Drach Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir Antimicrob Agents Chemother 54 2010 3093 3098
53. B.G. Gentry, S.N. Gentry, T.L. Jackson, J. Zemlicka, and J.C. Drach Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase Biochem Pharmacol 81 2011 43 49
54. S. Chou, and T.L. Bowlin Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility Antimicrob Agents Chemother 55 2011 382 384
55. M. Hakki, C. Drummond, B. Houser, G. Marousek, and S. Chou Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection Antiviral Res 92 2011 313 318
56. P. Lischka, G. Hewlett, T. Wunberg, J. Baumeister, D. Paulsen, T. Goldner, H. Ruebsamen-Schaeff, and H. Zimmermann In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246 Antimicrob Agents Chemother 54 2010 1290 1297
57. E. Bogner Human cytomegalovirus terminase as a target for antiviral chemotherapy Rev Med Virol 12 2002 115 127 (Pubitemid 34273046)
58. P.M. Krosky, M.R. Underwood, S.R. Turk, K.W. Feng, R.K. Jain, R.G. Ptak, A.C. Westerman, K.K. Biron, L.B. Townsend, and J.C. Drach Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56 J Virol 72 1998 4721 4728 (Pubitemid 28215647)
59. J. Reefschlaeger, W. Bender, S. Hallenberger, O. Weber, P. Eckenberg, S. Goldmann, M. Haerter, I. Buerger, J. Trappe, and J.A. Herrington Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action J Antimicrob Chemother 48 2001 757 767 (Pubitemid 33735310)
60. T. Goldner, G. Hewlett, N. Ettischer, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase J Virol 85 2011 10884 10893
61. D.R. Kaul, S. Stoelben, E. Cober, T. Ojo, E. Sandusky, P. Lischka, H. Zimmermann, and H. Rubsamen-Schaeff First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246 Am J Transplant 11 2011 1079 1084
62. J.A. Este, and T. Cihlar Current status and challenges of antiretroviral research and therapy Antiviral Res 85 2010 25 33